Related Experiment Video

Updated: Nov 17, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Emerging therapeutics in the management of COVID-19

Asim Kichloo1, Michael Albosta2, Akshay Kumar3

  • 1Department of Internal Medicine, Samaritan Medical Center, Watertown, NY 13601, United States.

World Journal of Virology
|February 15, 2021
PubMed

Insights

Currently, no COVID-19 treatments significantly reduce mortality. Many therapeutics are in clinical trials, and ongoing research is crucial for finding effective treatments for coronavirus disease 2019 (COVID-19).

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • The COVID-19 pandemic has overwhelmed global healthcare systems.
  • Evaluating therapeutic efficacy for COVID-19 is challenging due to limited clinical trial data.
  • A comprehensive review of COVID-19 therapeutics is lacking.

Purpose of the Study:

  • To review and elaborate on therapeutic strategies for COVID-19.
  • To detail the mechanism of action, clinical trial status, and adverse effects of each therapeutic.
  • To identify effective treatments for reducing COVID-19 morbidity and mortality.

Main Methods:

  • Literature review using PubMed, Google Scholar, and Clinicaltrials.gov.
  • Keywords included: "COVID-19", "therapeutics", "clinical trials", "treatment", "FDA", "ICU", "mortality", and "management".
  • Reference lists of retrieved articles were also searched.

Main Results:

  • No single treatment has proven effective in significantly reducing COVID-19 morbidity and mortality.
  • Numerous clinical trials are investigating a wide range of therapeutic agents.
  • Understanding mechanisms, trial outcomes, and side effects is essential for treatment selection.

Conclusions:

  • Ongoing research and analysis of past pandemic strategies are vital for discovering beneficial COVID-19 treatments.
  • Continued clinical trials are necessary to establish effective therapeutic interventions.
  • A coordinated approach to therapeutic development is needed to combat the pandemic.
Keywords:
COVID-19Infectious diseasePharmacologySARS-CoV-2TherapeuticsVirology

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.6K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
663
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
70
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
579
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
238
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
89